Article
Celltrion USA Announces Submission Of BLA For Subcutaneous Infliximab Biosimilar
On December 22, 2022, Celltrion USA announced that it submitted a Biologics License Application for a subcutaneous formulation of infliximab, CT-P13, to the U.S. Food and Drug Administration.
Goodwin Procter LLP




